IBI351 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Guangdong Association of Clinical Trials (1). The most-studied condition is Lung Cancer (Non-Small Cell).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
IBI351 Plus Cetuximab ฮฒ in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07198841 · ClinicalTrials.gov ↗ · Lung Cancer (Non-Small Cell)
|
Phase 2 | Recruiting | Guangdong Association of Clinical Trials | China |
|
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
NCT05504278 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer
|
Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Guangdong Association of Clinical Trials | 1 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name IBI351 (also registered as GFH925) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Guangdong Association of Clinical Trials (1) and Innovent Biologics (Suzhou) Co. Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IBI351 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how IBI351 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IBI351 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.